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The incidence and prevalence of invasive fungal infections have increased since the 1980s, 
especially in the population of immunocompromised patients and those who are hospitalized 
for long periods. Approximately 80% of invasive fungal infections are due to Candida species 
and 0.3–19% to Aspergillus species.  
Candida species belong to the normal microbiota of an individual’s mucosal oral cavity, 
gastrointestinal tract and vagina. Although this commensal organism normally colonizes 
mucosal surfaces in an asymptomatic manner, it can become one of the most significant 
causes of lethal infection. In the past decades, Candida species emerged as major causes of 
nosocomial infections, which are the third-fourth most common cause of bloodstream 
infections.  
The widespread use of intravascular devices (such as cannulas, catheters, prosthetic valves, 
endotracheal tubes, replacemect joints) in the past has paralleled the increasing incidence of 
catheter-associated infections. Candida species are the third most common cause of catheter-
associated bloodstream infections. In these infections the most frequently isolated species are 
C. parapsilosis complex (42.8%), and C. albicans (34.7%). 
Fungal biofilms complicates treatment because they increase resistance to antifungal 
therapies. The biofilm structure is intrinsically resistant to limited conventional antimicrobial 
drugs and host immune responses. Fungal biofilm formation inside or on the surface of the 
catheters can be a major source of invasive candidiasis. Currently IDSA (Infectious Diseases 
Society of America) guidelines support removal, and/or replacement of catheters to prevent 
the formation of biofilm on surfaces of these devices; however, this practice is not always 
feasible due to the patient’s condition. 
An alternative solution can be the use of special therapies, such as antifungal lock therapy; 
however there is no officially approved antifungal lock therapy to treat Candida biofilm. Out 
of the traditional antifungal agents currently in clinical use only amphotericin B (AmB) and 
the echinocandins have consistent activity against biofilms, but on their own they are not 
always effectives. A new, innovative solution could be to combat biofilms using antifungal 
agents in combination with special communication quorum-sensing molecules produced by 
Candida species. During Candida biofilm formation extracellular signalling molecules 
accumulate in the extracellular matrix, that coordinate their metabolic activities and gene 
expression promote their survival. Previous studies have shown that certain quorum-sensing 
molecules in supraphysiological concentration inhibits growing fungal cells within the 
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biofilm. Based on our presumption supraphysiological/high concentrations of this compound 
confuses the communication between the Candida cells, thereby weakening the compact 
structure of the biofilms and allowing penetration of traditional antifungals inside the biofilm. 
It is important in the case of C. parapsilosis, which is innately less susceptible to antifungal 
drugs which have antifungal effect, like echinocandins. The aim of our study was to reveal the 
expected in vitro synergizing effect of quorum-sensing molecules derived from Candida 
species and to illuminate the potential therapeutic advantage of these communication 
molecules. Our findings support the development of new alternative therapeutic strategies 





The primary aim of our study was to determine new antifungal strategies which help eradicate 
the biofilm-associated infections caused by C. albicans and C. parapsilosis. In our 
experiments we combined traditional antifungal agents with quorum-sensing molecules - 
farnesol - derived from fungi, to increase this component’s in vitro and in vivo efficacy. 
 
The aim of our study was: 
 
 To determine the minimal inhibitory concentrations of caspofungin, micafungin and 
farnesol against planktonic and sessile C. parapsilosis clinical isolates 
 
 To examine the interaction between caspofungin, micafungin and farnesol against 
sessile cells formed by C. parapsilosis clinical isolates by a two-dimensional broth 
microdilution assay. 
 
 To examine the reduction of metabolic activity over time by caspofungin, micafungin 
and farnesol against sessile cells formed by C. parapsilosis clinical isolates. 
 
 To determine the minimal inhibitory concentrations of fluconazole and farnesol 
against planktonic and sessile cells formed by fluconazole-sensitive and fluconazole-
resistant clinical isolates of C. albicans. 
 
 To examine the in vitro effect of fluconazole and farnesol in combination against 
fluconazole-sensitive and fluconazole-resistant planctonic and sessile clinical isolates 
of C. albicans. 
 
 To evaluate the in vivo effects of fluconazole and farnesol alone and combination on 
vaginal fungal burden in a murine vulvovagintis model. 
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MATERIALS AND METHODS 
 
Isolates 
We examined five C. parapsilosis sensu stricto (16641, 17432, 17818, 10252, 9613), two 
fluconazole (FLU)-sensitive (1216, 10431) and two FLU-resistant (21616, 27700) C. albicans 
clinical isolates and two reference strains [C. parapsilosis ATCC 22019 (American Type 
Culture Collection), (C. albicans SC5314)]. All tested C. parapsilosis clinical isolates 
originated from blood culture, and C. albicans clinical isolates were isolated from 
vulvovaginal candidiasis. The C. parapsilosis and C. albicans clinical isolates were identified 
by API® ID32C (bioMérieux, Marcy-l’Étoile, French) and MALDI-TOF [(Matrix-assisted 
laser desorption/ionization time of flight), (Microflex, Bruker Daltonics, Bremen, Germany)]. 
Biofilm production of the examined C. parapsilosis, C. albicans clinical isolates, and 
reference strains was verified using a crystal violet assay by Marcos-Zambrano et al. 
 
Susceptibility testing of planktonic cells 
Minimum inhibitory concentrations (MICs) of caspofungin (CAS) (pure powder; Sigma, 
Budapest, Hungary), micafungin (MICA) (pure powder; Astellas Pharma Inc., Tokyo, Japan) 
FLU (Sigma) and farnesol (Sigma) were determined using the broth microdilution method in 
RPMI-1640 with L-glutamine and without bicarbonate (pH 7.0) with MOPS  
[3-(Nmorpholino) propanesulfonic acid] (Sigma) according to Clinical and Laboratory 
Standards Institute (CLSI) standard M27-A3 protocol. We used C. parapsilosis ATCC 22019 
and C. krusei ATCC 6258 as quality controls. 
The isolates of both species’ final drug concentrations ranged between 0.06 and 4 mg/L for 
CAS, MICA and FLU in the case of susceptible isolates, between 2-128 mg/L for FLU in the 
case of resistant isolates, and between 1.17-300 µM for farnesol in the case of all isolates. 
The working concentrations of the drugs were prepared in RPMI-1640 (Sigma). Each drug-
free control well contained 1% (v/v) methanol. The inoculum was 0.5–2.5  103 cells/mL. 
Susceptibility testing for planktonic cells was carried out in 96-well plates at 37°C for 24 h. 
MICs were defined based on turbidity (492 nm) as being at least 50% growth reduction 
compared with the drug-free control. Percentage change in turbidity was calculated on the 
basis of absorbance (A) as 100% × (Awell – Abackground)/(Adrug-free well – Abackground). The 
background was measured from the fungus-free well. All isolates were tested in three 




Biofilms were prepared as described by Pierce et al. Isolates were subcultured on Sabouraud 
dextrose agar for two consecutive days and then the renewed strains were plated onto 1-1 
Sabouraud agar plates again per isolates. The grown isolates were taken from the surface of 
the agar plates with a sterile swab and suspended in 25 mL sterile physiological saline. The 
suspensions were centrifugated for 10 minutes at 3000 g. We removed the supernatant from 
the cells after the centrifugation and added 25 mL fresh, sterile physiological saline to them 
again and repeat the last step. After the last centrifugation we removed the supernatant again 
and added 5-6 mL of sterile saline to the fungal cells. We then counted the suspension using a 
Burker chamber of each isolates. The final density of the suspension was 1  106 CFU/mL in 
RPMI-1640 as also confirmed by quantitative culture. A total of 100 L of the C. parapsilosis 
and C. albicans suspension was pipetted into polystyrene flat-bottom 96-well microtitre plates 
(TPP, Trasadingen, Switzerland) and was then sealed with Parafilm and incubated statically 
for 24 h at 37 C. After the incubation time, the medium was removed and the plates were 
washed three times. Negative control wells contained 100 µL of RPMI-1640. 
 
Biofilm mass determination  
To determine the biofilm mass one-day-old biofilms were washed three times with 200 L of 
sterile physiological saline. In brief, 125 μl of a 0.1% crystal violet solution was added to each 
well containing prewashed biofilms and incubated for 15 min at room temperature. The 
solution was then removed and plates were washed three times with 200 μl physiological 
saline to remove excess crystal violet completely. Afterwards 125 μl of a 30% acetic acid 
solution was added to each well to solubilize the biofilm bound crystal violet. After 15 min 
incubation at room temperature, 100 μl supernatant was transferred to a new 96-well plate and 
read spectrophotometrically at 540 nm. Blank wells contained 100 μl of 30% acetic acid. 
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Susceptibility testing of biofilms 
The examined concentrations for MIC determination in C. parapsilosis biofilms were  
4–256 mg/L, 2–512 mg/L and 1.17–300 M for CAS, MICA and farnesol, respectively. CAS 
and MICA concentrations ranged between 0.5–32 mg/L for the sessile C. parapsilosis ATCC 
22019 reference strain. The concentrations tested in MIC determination in C. albicans 
biofilms were 8–512 mg/L and 1.17– 300 μM for FLU and farnesol, respectively. To 
determine the 24-h biofilm MICs, the one-day-old biofilms were first washed three times with 
200 μl sterile physiological saline. All wells, including the blank ones, were filled with 100 μl 
of 0.5 g/L XTT/1 μM menadione solution. The plates were covered with aluminium foil and 
incubated at 37°C for 2 h. After incubation, 80 μl of the supernatant was removed and 
transferred into a new 96-well plate in order to measure the absorbance 
spectrophotometrically at 492 nm. MICs were defined as the lowest concentration that 
produced at least 50% reduction in metabolic activity of fungal biofilms. The percentage 
change in metabolic activity was calculated in the same way as described for the measurement 
of turbidity for planktonic cells. All isolates were tested in three independent experiments and 
the median of the three values was used in the analysis. 
 
Interactions between caspofungin, micafungin, fluconazole and farnesol 
Drug interactions were measured by a two-dimensional broth microdilution checkerboard 
assay both for planktonic and sessile cells. The concentration ranges were same as described 
above for MIC determination against planktonic cells and biofilms. A fractional inhibitory 
concentration index (FICI) was used to assess the drug interactions between farnesol and 


















 are the MICs of agents A and B when acting in combination, 
respectively. The FICI was defined as the lowest FIC. The MIC values of the drugs alone 
and of all isoeffective combinations were determined as the lowest drug concentrations 
showing at least 50% reduction of turbidity for planktonic or at least 50% reduction of 
metabolic activity for sessile cells compared to the untreated controls. The interaction 
between the drugs was interpreted as synergistic when FICI was ≤ 0.5, as indifferent 
interaction when FICI was between > 0.5 and 4 and as antagonistic when FICI was > 4. 
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Examination the changes of metabolic activity over time 
The findings of fractional inhibitory concentration index were confirmed by other method, 
thus we investigated the changes of metabolic activity over time for sessile C. parapsilosis 
and C. albicans cells. Using this method provide more accurate information about the efficacy 
and dynamic of drugs alone and combination.F The in vitro efficacy of CAS and MICA and 
combination with farnesol was studied on C. parapsilosis and the FLU alone and in 
combination with farnesol against C. albicans sessile cells. Based on the results of the XTT 
assay, three CAS and MICA concentrations were chosen (4, 8 and 16 mg/L) and their 
antibiofilm effect alone and in combination with 75 M farnesol was examined. The drug 
concentrations tested in the experiments over time were 0.5 mg/L, 8 mg/L, 64 mg/L, and  
512 mg/L FLU with and without 75 μM farnesol against the FLU-sensitive strains and against 
the reference strain, as well as 64 mg/L, 128 mg/L, 256 mg/L, and 512 mg/L FLU with and 
without 75 μM farnesol against the two resistant strains.  
After the biofilms were prepared, one-day-old biofilms were washed three times with 200 L 
of physiological saline. Predetermined wells were assigned to endpoints of 3, 6, 9, 12, and  
24 hours, then the different drug concentrations were added in RPMI-1640 to all wells at time 
0. After 3, 6, 9, 12, and 24 hours, the corresponding pre-assigned wells were washed in both 
plates and the biofilm mass as well as the metabolic activity of biofilms was measured as 
described above. Baseline biofilm mass and metabolic activity was measured from wells 
assigned as such prior to adding the drug. All isolates were tested in three independent 
experiments. Baseline metabolic activity was measured without adding the drug. 
Experimental results are presented in diagrams which were prepared from the measured 
metabolic activity values using GraphPad Prism 6.05. 
 
Data analysis 
One-way ANOVA with Dunnett’s post-testing was used to analyse the biofilm mass and the 
reduction in metabolic activity caused by the drug alone and in combinations compared with 
the drug-free control. Concentrations with and without farnesol were compared with each 
other using one-way ANOVA with Sidak’s post-testing. Significance was defined as p<0.05. 
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In vivo experiments 
Animals 
In our experiments we used BALB/c immunocompetent female mice (22-23 g) (Charles 
River), which were maintained in accordance with the Guidelines for the Care and Use of 
Laboratory Animals. Each group consisted of ten animals. The permission number of the in 
vivo experiment: 12/2014 DEMÁB. 
 
Infection of the mice 
Mice were administered 50 μl subcutaneous estradiol-valerat (10 mg/ml in sesame seed oil) 
three days prior to vaginal infection. For the infectious doses we plated the isolates of  
C. albicans onto Sabouraud agar plates on two consecutive days and then the renewed strains 
were plated onto 3-4 Sabouraud agar plates again. After 24 hours incubation at 35 ºC the 
grown isolates were taken from the surface of the agar plates with a sterile swab and 
suspended in sterile saline. The suspensions were centrifugated for 10 minutes at 3000 g then 
we removed the supernatant from the cells. After the centrifugation we added 25 mL fresh, 
sterile physiological saline to them and centrifugated again. The suspensions were washed 
four times and after the last centrifugation we removed the supernatant and added 8 mL of 
sterile saline to the fungal cells. From this cell suspension we prepared 10-fold dilution in two 
steps and adjusted the required cell count of the infectious dose with Burker chamber. 
Inoculum density was confirmed by plating serial dilutions on Sabouraud dextrose agar. In 
accordance with our preliminary experiments, animals were infected intravaginally with  
1–1.2 × 107 CFU in 25 μl physiological saline. 
 
Antifungal therapy 
All regimens were started 24 h postinfection: i) control; ii) 5 mg/kg/day; iii) 35 mg/kg 
fluconazole in a single dose; iv) 150 μM/day farnesol; v) 300 μM/day farnesol; 5 mg/kg/day 
fluconazole combined vi) with 150 μM/day farnesol and vii) with 300 μM/day farnesol. 
All regimens were started 24 h postinfection. FLU doses were administered intraperitonally at 
a volume of 0.5 ml, while farnesol was given intravaginally at a volume of 25 μl one hour 
after the FLU treatment. Farnesol was diluted in 0.25% Tween 80 solution. Control mice were 
given 0.5 ml physiological saline intraperitonally as well as 25 μl 0.25% Tween 80 solution 
without farnesol intravaginally. At 4 days postinfection, mice were euthanized and their 
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vaginae were excised, weighed and homogenized aseptically. Homogenates were diluted  
10-fold, aliquots of 100 µL of the diluted and undiluted (1:10) homogenates were plated onto 
Sabouraud agar plates and incubated at 35 ºC for 48 hours. Vaginal burden was analyzed 
using the Kruskal-Wallis test with Dunn’s post-test (GraphPad Prism 6.05.). Significance was 





Susceptibility testing of planktonic Candida parapsilosis isolates to caspofungin and 
farnesol using broth microdilution method 
One of the tested C. parapsilosis clinical isolates (9613) and the reference strain (ATCC 
22019) were susceptible, but isolates 16641, 17432, 10252 and 17818 were intermediate to 
caspofungin according to CLSI breakpoints. 
The median MICs observed for caspofungin in combination with farnesol showed a 2-64-fold 
decrease. Farnesol MIC was reduced 4-32-fold in combination with farnesol. In the case of 
reference strain ATCC 22019 a 2-8-fold MIC decrease was detected in combination. 
 
Susceptibility testing of sessile Candida parapsilosis isolates to caspofungin and farnesol 
using broth microdilution method 
The median MICs for CAS against sessile cells formed by clinical isolates showed higher 
value (32-256 mg/L) to that of planktonic form. In combination with farnesol MICs values 
decreased these rates to 4 mg/L against all tested clinical isolates. This reduction in median 
MICs was equal 8-64-fold reduction but the median MICs for farnesol was changed 4-32-fold 
reduction to that of the planktonic form. The measured median MICs in the case of reference 
strain ATCC 22019 showed only one dilution degree. The median MICs for CAS against the 
planktonic strain C. parapsilosis ATCC 22019 for CAS was equal to the sessile form  
(2 mg/L), probably due to its poorer biofilm production. 
 
Examination of the in vitro interactions between caspofungin and farnesol against 
Candida parapsilosis clinical isolates 
For the combination of CAS and farnesol we observed indifferent interaction in all tested 
planktonic clinical isolates except for 17432. Synergy between farnesol and CAS was 
observed for all clinical isolates when grown in biofilm (FICImedian: 0.155-0.5). Antagonism 
was never observed (all FICIs ≤ 4). In case of the ATCC reference strain we observed 





The changes of the metabolic activity in sessile cells formed by Candida parapsilosis by 
caspofungin and farnesol 
Simultaneously to the above mentioned method the changes of the metabolic activity of 
treated cells were compared to the changes of the metabolic activity of untreated sessile cells. 
The chosen CAS concentrations (4 mg/L, 8 mg/L, 16 mg/L) alone did not significantly inhibit 
the metabolic activity of sessile clinical isolates in the first 3 hours compared with control 
biofilms. However, a significant reduction was observed between 6-24 hours in a 
concentration dependent manner. In combination with 75 M farnesol(4 mg/L+75 µM,  
8 mg/L+ 75 µM, 16 mg/L+ 75 µM), a significant reduction in metabolic activity was 
observed for all sessile clinical C. parapsilosis isolates at each tested time point  
(p<0.05–0.001) compared with control biofilms. Nevertheless, after the first twelve hours 
where the marked reduction in metabolic activity was inherent, we observed slow growing, 
meaning that the combination was the most effective in the first twelve hours. Farnesol in 
combination with CAS (8 and 16 mg/L) was significantly better/more effective compared 
with CAS alone between 3-24 hours (p<0.001-0.05). CAS (4 mg/L) in combination with 
farnesol was significantly better just in the first 9 hours compared CAS without farnesol 
(p<0.001-0.05). 
 
Susceptibility testing of planktonic Candida parapsilosis isolates to micafungin and 
farnesol using broth microdilution method 
The tested C. parapsilosis isolates (16641, 17818, 10252) and the reference strain (ATCC 
22019) were susceptible and intermediate to MICA according to CLSI breakpoints. In the 
cases of clinical isolates MICA in combination with farnesol caused a 2-64-fold 
decreasecompared with the median MICs of MICA alone. For clinical isolates, farnesol in 
combination with MICA farnesol MICs was reduced 16-256-fold. In the case of planktonic 
ATCC 22019 reference strain 8-16-fold MIC decrease was detected in combination. 
 
Susceptibility testing of sessile Candida parapsilosis isolates to micafungin and farnesol 
using broth microdilution method 
Upon examination of the sessile cells formed by clinical isolates the measured median MICs 
were higher (16-512 mg/L) compared with planktonic cells. Median MICs for MICA in 
combination with farnesol decreased their rates 4-8 mg/L. Median MICs for farnesol showed 
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an 8-16-fold decrease in combination. In the case of ATCC 22019 a 2-fold MIC reduction 
was observed. The measured median MIC for MICA against the sessile sessile strain ATCC 
22019 was equal to that of the planktonic form (1 mg/L). 
 
Examination of the in vitro interactions between micafungin and farnesol against 
Candida parapsilosis clinical isolates 
The FICI values were under 4 all times, antagonism was never observed. Synergy between 
MICA and farnesol was observed for all planktonic and sessile clinical isolates. In case of the 
sessile cells the synergistic interaction was proved by FICI ≤0.5 values. We observed ≥0.5 
values in several tested planktonic clinical isolates (17818, 10252, 9613). In the case of 
ATCC 22019 we observed indifferent interaction against planktonic and sessile cells. 
 
The changes of metabolic activity for micafungin and farnesol against sessile cells 
formed by Candida parapsilosis 
We can see in the dynamics of metabolic activity changes that MICA like CAS had a 
concentration-dependent effect on the metabolic activity of biofilms was observed for:  
4 and 8 mg/L MICA in the first 9 hours (p˂0,05-0,001), but 16 mg/L MICA in the first 12 
hours decreased significantly the metabolic activity compared with the control (p˂0,001). At 
24 hours, we did not detect significantly difference compared to the untreated cells, the 
metabolic activity of fungal cells increased steadily. A significant reduction in metabolic 
activity was observed for all three tested MICA concentration combined with farnesol  
(4 mg/L+75 µM, 8 mg/L+75 µM, 16 mg/L+75 µM) in the first 12 hours (p˂0,001). 
At 24 hours metabolic activity was similar levels to controls, therefore the inhibition of the 
metabolic activity was partially observed. Unlike the CAS, MICA triggered a marked 
reduction in metabolic activity in the first 9 hours in combinations. However, after the 9 hours 
the metabolic activity of fungal cells increased steadily, reaching similar levels to controls. 
Despite this increase, the metabolic activity of sessile fungal cells was significantly lower for 
all of three combinations between 3 and 12 hours compared with the control (p<0.001).  
It is noteworthy that paradoxical growth was observed for several clinical isolates. 
Paradoxical growth was observed exclusively in the sessile cells. This effect was revealed 
between 32–128 mg/L and 64–512 mg/L concentrations for CAS and MICA, respectively 
which was eliminated by addition of farnesol.  
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Susceptibility testing of planktonic Candida albicans isolates to fluconazole and farnesol 
using broth microdilution method 
Two out of four tested planktonic clinical isolates and the reference strain were susceptible 
(SC5314, 1216, 10431), while isolates 27700 and 21616 were resistantto FLU according to 
CLSI breakpoints. Farnesol had no effect alone regardless of the FLU susceptibility of 
planktonic isolates. The MICs of farnesol in combinations decreased, however it was 
primarily the effect of FLU that dominated in these combinations. 
 
Susceptibility testing of sessile Candida albicans isolates to fluconazole and farnesol 
using broth microdilution method 
In combination (FLU and farnesol) farnesol caused a 2- to 64-fold decrease in the median 
FLU MICs against biofilms. Furthermore, median farnesol MIC values exhibited a 2- to  
4-fold reduction in combination with FLU for sessile cells. 
 
Examination of the in vitro interactions between fluconazole and farnesol against 
Candida albicans clinical isolates 
With the combination of FLU and farnesol only indifferent interactions were detected in the 
case of planktonic isolates. For biofilms, synergy between FLU and farnesol was observed 
only against the reference strain SC5314. Against other sessile clinical isolates, the interaction 
was indifferent, similar to the findings with planktonic forms. Antagonism was never 
observed (FICIs<4). 
 
The changes in metabolic activity for fluconazole and farnesol against sessile cells 
formed by Candida albicans 
Concentration- and time-dependent action of the drugs on the metabolic activity of biofilms 
was observed for all three FLU-sensitive C. albicans isolates. Significant reduction was 
observed for all tested FLU concentrations (alone and in combination) at 24 hours compared 
with the control curve (p< 0.01–0.001). The highest tested FLU concentration (512 mg/L) 
with farnesol (75 µM) was effective even at 6 hours (p< 0.05). There were no significant 
differences between the given concentrations alone and the corresponding combinations  
(0.5 mg/L vs. 0.5 mg/L+75 μM, etc.) (p>0.05). In the case of resistant isolates, a marked 
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reduction in metabolic activity was observed at 6 hours for all tested FLU concentrations (p< 
0.001); however, metabolic activity showed transitional increase between 6 and 12 hours. Yet, 
at 24 hours significantly reduced metabolic activity was observed for treated cells compared 
to the control biofilm for all concentrations (p< 0.001). At 24 hours, only the 256 mg/L +  
75 μM combination caused a significantly higher reduction in metabolic activity compared to 
the corresponding concentration alone (256 mg/L) (p> 0.001). 
 
Examination of the in vivo efficacy of fluconazole using mouse vulvovaginitis model 
In our in vivo experiments we used two FLU-susceptible and two FLU-resistant isolates. 
Against both FLU-susceptible C. albicans clinical isolates (1216, 10431), 5 mg/kg/day and 
asingle dose of 35 mg/kg proved to be able to decrease the vaginal fungal burden significantly 
(p<0.05–0.001). 
Furthermore, the regimens of 5 mg/kg/day with 150 μM/day and 300 μM/day farnesol were 
also effective compared to control mice (p<0.05–0.001). Neither farnesol dose was effective 
alone compared to untreated mice (p>0.05). Against the FLU-resistant isolate 21616, the 
regimen of 5 mg/kg/day of FLU was ineffective, but when combined with farnesol it reduced 
vaginal burdens significantly, regardless of farnesol dose (p< 0.05–0.01). The higher FLU 
dose [(35 mg/kg mouse dose, approximately corresponding to the normal human dose of  
150 mg based on 24h- AUC (area under curve)] was effective alone. Nevertheless, in multiple 
comparisons (5 mg/kg/day + 150 µM/day farnesol; 5 mg/kg/day + 300 µM/day farnesol) none 
of the combinations were superior to the single dose of 35 mg/kg FLU (p>0.05). Against the 





The past decades have witnessed a dramatic increase in invasive fungal infections caused by 
different Candida species, especially in immunocompromised individuals with a prolonged 
hospital stay. Nowadays the most frequent isolated species is the C. albicans but the latest 
epidemiological data have shown the invasive infections caused by non-albicans species  
(C. parapsilosis C. glabrata, C. tropicalis, C. krusei) increasing continuously. Considering 
the biofilm forming ability on biotic (host tissues) and abiotic surfaces (implanted medical 
devices), relatively few antifungal drugs can penetrate the biofilms associated with high 
mortality rate.  With the antifungal drugs used in systemic infections only different AmB 
formulations (amphotericin B lipid complex, liposomal amphotericin B) and echinocandins 
can penetrate the biofilms. Echinocandins are not the primary teratment used in the case of  
C. parapsilosis, because this species has reduced echinocandin susceptibility. This naturally 
associated with mutations in the conserved regions of FKS. In the course of catheter-
associated infections caused by fungi, catheter removal is recommended in addition to the 
systemic antifungal therapy. This procedure does not always have better outcome, because 
biofilm can reproduced (24-48 hours) quickly on the surface of the indwelling devices, 
moreover the primer adherence form after the first 90 minutes. Removal and replacement of 
devices is painful surgical procedure for the patients and costly.  
The prevention of biofilm formation – and catheter-associated infections- can be achieved by 
coating or impregnating them with antimicrobial drugs.  
Using the impregnated catheters is a costly method in the treatment of catheter-associated 
infections, but a more innovative and cheaper technique is antifungal lock therapy, which is 
employed in the case of antibiotics in clinical practice. Antifungal lock therapy utilizes 
prolonged instillation of a solution containing high concentrations of antimicrobial agents in 
an infected intravascular catheter then rinsing and opening it. 
Antifungal lock therapy has recently been recommended by current IDSA guidelines as a 
first-line option for the management of catheter-related bloodstream infections caused by 
coagulase-negative staphylococci and gram-negative bacteria; however, in the case of fungi 
there are no officially accepted guidelines. Based on previous reports, quorum-sensing 
molecules produced by C. albicans (farnesol) can increase the activity of certain antifungal 
drugs and may be potential adjuvants in the treatment of infections caused by different 
Candida species. The research examined only the effect against C. albicans. Our research 
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group examined the in vitro potential adjuvant activities of farnesol combined with 
caspofungin and micafungin against five different C. parapsilosis biofilms. 
Based on our hypothesis, the exogenous farnesol in supraphysiological concentration 
disrupted the communication and metabolic activity of Candida cells in the biofilms 
(ergosterol synthesis pathway) and made them more susceptible to farnesol combined with 
traditional antifungal agents. 
Therefore, the generic lower susceptibility of C. parapsilosis against echinocandins (which is 
markedly increased in biofims) can be decreased. 
In our experiments against planktonic C. parapsilosis cells the median MICs observed for 
CAS in combination with farnesol showed a significant decrease (2-64 fold; 4-32 fold) 
compared with MICs of CAS and farnesol alone. MICA in combination with farnesol caused 
a similar degree of reduction (2-64 fold; 4-32 fold). For the combination of CAS and farnesol 
we observed indifferent interaction in all tested planktonic clinical isolates except for 17432; 
however our calculated median FICI values were very close to the synergy threshold in most 
isolates (median FICI: 0.375-0.75). 
We observed synergistic interactions for MICA and farnesol against all tested C. parapsilosis 
clinical isolates (median FICI: 0.131-0.5). 
The biofilm-based results demonstrated consistent synergistic interactions both for 
CAS+farnesol and MICA+farnesol combinations against all tested C. parapsilosis clinical 
isolates. CAS combined with farnesol caused 8-64-fold reduction, MICA and farnesol 
reduced the MICs 4-32-fold compared to the median MICs alone. Based  on  FICIs  for  
sessile  clinical  isolates,  synergism  was  observed  for  CAS (range  of  median  FICIs,  
0.155–0.5)  and  MICA  (range  of  median  FICIs,  0.093–0.5).   
Based on FICI values the presence of synergy for biofilm also confirmed changes in 
metabolic activity investigations. A significant reduction in metabolic activity was detected 
with all tested combinations at all time points for CAS, while significant inhibition in 
metabolism was observed only in the first 12 hours for MICA. 
It is noteworthy that indifferent interactions were observed for planktonic and sessile cells of 
the C. parapsilosis ATCC 22019 strain probably due to its poorer biofilm production and its 
ability to form thinner biofilm layer. Farnesol consistently enhanced the activity of CAS and 
MICA against 1-day-old C. parapsilosis biofilms, as concordantly shown in two independent 
experimental settings.  
In treatment of the biofilm-associated infections the azol-type antifungals does not suggested 
primarily, but exogenous quorum-sensing molecules are able to enhance the activity of 
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various traditional antifungal drugs against Candida biofilms. Perhaps may be utilize the 
augmentation of the antimicrobial efficacy of farnesol in the therapy of mucosal infection. 
Previous studies described that farnesol shows in vitro synergistic interaction with different 
azoles against C. albicans which was confirmed by using immunocompetent murine 
vulvovaginitis model. Candida biofilm can form in the host cells and tissues of the oral cavity 
and respiratory, gastrointestinal and urinary tracts. Among women biofilm most frequently 
forms in the mucosal vaginal cavity, which leads to recurrent vulvovaginal candidiasis. Based 
on previous epidemiological studies vulvovaginitis caused by Candida species pose a major 
threat to public health, thus discovery of new compounds with antibiofilm activity has 
become more important due to the emergence resistance to most azol-type antifungal agents.  
Cornerstone of antifungal drug therapy can be utilize quorum-sensing molecules as potential 
adjuvants in case of various alternative treatment strategies for disruption the biofilms on the 
surface of the vaginal epithelium. 
Our in vitro research demonstrates indifferent interaction for all tested planktonic isolates, 
including the reference strain SC5314 in case of FLU combined with farnesol. The present 
study reports in vitro synergistic interaction against sessile SC5314 as shown by FICI. 
Notably, this was never observed agaist biofilms formed by clinical isolates, where only 
indifferent interactions were detected. 
Despite the uniform behavior of the clinical isolates was observed unusual physiological 
properties in some cases. In the case of sessile azole-resistant isolates, checkerboard 
microdilution revealed paradoxically enhanced metabolic activity with high FLU and farnesol 
concentrations as compared to control wells. It was reported previously that exogenous 
farnesol exposure may up-regulate genes of the central carbon-metabolic pathways including 
glycolysis, gluconeogenesis, acetyl-CoA pathway, nitrogen metabolism and amino acid 
biosynthesis, which may explain the observed paradoxical enhancement of metabolic activity.  
Presumably, this phenomenon occurred in experiments over time with the resistant isolates 
(21616, 27700) accounting for the transitionally increased metabolic activity observed 
between 6–12 hours. Based on our in vivo findings neither 150 μM nor 300 μM farnesol alone 
had a protective effect against vaginal Candida infection. However, against the FLU-resistant 
isolate 21616, both farnesol regimens administered enhanced the activity of 5 mg/kg daily 
FLU significantly as compared to the untreated control mice (p˂0.05-0.01). 
In our in vitro experiments we observed indifferent interaction in all tested planktonic islates; 
however the only FLU-susceptible wild-type isolate against which farnesol enhances the in 
vitro activity of FLU consistently is the reference strain SC5314. 
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Nevertheless, the clinical importance of farnesol as a potential adjuvant remains questionable 
(21616 was the only isolate in this study where farnesol was able to enhance the in vivo 
activity of FLU and the effect was relatively small) and seems to be confined to FLU-resistant 
isolates. 
In summary, this is the first study to our knowledge that examines the effect of farnesol alone 
and in combination with FLU in vivo. This work documented that vaginal administration of 
farnesol alone did not have protective effect in murine vulvovaginitis and it did not 
consistently enhance the effect of FLU either in vitro or in vivo against C.albicans clinical 
isolates. This indicates that in vitro findings are not directly applicable for predicting in vivo 
utility of farnesol as adjuvant; further in vivo experiments are needed to clarify the effect of 





Biofilms may be a potential source of invasive candidiasis and mucosal infections. The 
primary aim of this study was to examine a potential adjuvant which would enhance the  
in vitro and in vivo activity of antifungal agents used in the treatment. Previous in vitro data 
suggest that certain quorum-sensing molecules (e.g. farnesol) may potentiate the activity of 
antifungal agents, hence they may be used as an adjuvant in alternative treatment strategies. 
During the first part of our investigations in vitro interactions were examined between 
caspofungin, micafungin and farnesol using two-dimensional broth microdilution assays then 
followed the changes of metabolic activity against C. parapsilosis biofilms. Then in vitro and 
in vivo activity of fluconazole was studied alone and in combination with farnesol against  
C. albicans biofilms using classical broth microdilution „checkerboard” assay and a murine 
vulvovaginitis model. The median sessile MICs ranged between 32-256 mg/L and  
16-512 mg/L for caspofungin and micafungin, respectively. Median MICs for caspofungin 
and micafungin in combination with farnesol decreased these rates to 4-8 mg/L. Based on 
FICIs for sessile clinical isolates, synergism was observed for caspofungin (range of median 
FICIs: 0.155-0.5) and micafungin (range of median FICIs: 0.093-0.5). The metabolic activity 
of fungal cells was inhibited by caspofungin+farnesol in all three tested combinations 
between 3 and 24 hours compared to the control (p˂0.05-0.001). Significant inhibition was 
observed for micafungin+farnesol in the first 12 hours (p˂0.001). In the case of sessile  
C. albicans cells farnesol caused a 2-64-fold MIC decrease in median MICs. For biofilms, 
synergy between fluconazole and farnesol was observed only against the reference strain 
(FICIs: 0.16-0.27). In vivo findings revealed that farnesol alone was not protective in a murine 
vulvovaginitis model, but in combination it can enhance the effect of fluconazole against 
fluconazole-resistant isolates of C. albicans. Our results suggest that farnesol may be a 
potential adjuvant in special therapies (e.g. antifungal lock therapy) in the catheter-associated 
infections caused by C. parapsilosis, but further in vivo studies are needed to confirm its anti-
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